GT 001 - Gila Therapeutics

Drug Profile

GT 001 - Gila Therapeutics

Alternative Names: GT-001; Peptide YY (3-36); Peptide YY3-36; PYY(3-36); PYY3-36

Latest Information Update: 12 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Gila Therapeutics
  • Class Obesity therapies; Peptides
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Obesity

Most Recent Events

  • 12 Apr 2018 Gila Therapeutics intends to initiate second clinical study in 2018 (Gila Therapeutics pipeline, April 2018)
  • 09 Aug 2017 Gila Therapeutics completes a phase I trial in Obesity (In volunteers) in USA (NCT03490786)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top